-
Two-Thirds Of Physicians Say Psilocybin Therapy Can Help Treatment-Resistant Depression, New Survey Shows
Wednesday, January 19, 2022 - 2:35pm | 504Read More...Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ: CMPS) and Sermo announced on Wednesday findings from a survey of Sermo physician members that showed two-thirds of doctors surveyed believe psilocybin therapy has potential therapeutic benefit for patients with treatment-...
-
Psilocybin Therapy Combined With SSRI Antidepressants Is Possible, COMPASS Study Confirms
Monday, December 13, 2021 - 10:56am | 605Read More...Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ: CMPS) announced Monday it had achieved positive results from its exploratory study of COMP360 psilocybin therapy in conjunction with SSRI use. SSRI, or selective serotonin reuptake inhibitors, are the most commonly...
